GLP-1 medications—semaglutide (Wegovy) and tirzepatide (Zepbound)—work by mimicking glucagon-like peptide-1, an intestinal hormone that regulates appetite, slows gastric emptying, and enhances insulin secretion. In randomized controlled trials, these agents produce 15-22% total body weight loss over 68-72 weeks when combined with lifestyle modification. We prescribe them for patients who meet evidence-based criteria and who understand that successful outcomes require metabolic monitoring, protein prioritization, and resistance training to preserve lean mass.
How do GLP-1 medications produce weight loss?
GLP-1 receptor agonists bind to GLP-1 receptors in the pancreas, stomach, and hypothalamus. This binding slows gastric emptying by up to 70%, creating sustained fullness after smaller meals. Centrally, the medications reduce appetite signaling in the arcuate nucleus and increase satiety signaling in the paraventricular nucleus. The STEP 1 trial demonstrated that semaglutide 2.4 mg weekly produced a mean weight loss of 14.9% versus 2.4% with placebo at 68 weeks. Tirzepatide, a dual GLP-1/GIP receptor agonist, showed even greater efficacy in the SURMOUNT-1 trial—patients on the 15 mg dose lost 22.5% of body weight at 72 weeks.
These medications also improve pancreatic beta-cell function and insulin sensitivity. Fasting insulin levels typically drop 30-40% within 12 weeks, reducing the hyperinsulinemia that drives fat storage and hunger. The FDA approved semaglutide for chronic weight management in June 2021 and tirzepatide in November 2023, both requiring BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity.
Who should consider GLP-1 medications for weight loss?
We evaluate candidacy using both anthropometric and metabolic criteria. The evidence-based threshold is BMI ≥30 kg/m² or BMI ≥27 kg/m² with hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea. But BMI alone is insufficient—we also assess body composition, particularly visceral adipose tissue and lean mass percentage, because sarcopenic obesity carries unique risks during rapid weight loss.
Metabolic phenotyping matters more than weight alone. A patient with BMI 28, elevated fasting insulin (>15 µIU/mL), HbA1c 5.9%, and high triglyceride-to-HDL ratio has a very different risk profile than someone with the same BMI and normal metabolic markers. The American Diabetes Association guidelines emphasize individualized treatment based on cardiometabolic risk, not weight thresholds alone. We also screen for contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior pancreatitis, severe gastroparesis, or active gallbladder disease.
Age and baseline muscle mass influence our recommendation. Patients over 65 or those with low lean mass (DEXA showing appendicular skeletal muscle index below sex-specific cutoffs) require more aggressive protein targets and supervised resistance training before and during treatment.
What biomarkers do we measure before prescribing GLP-1 medications?
We run a metabolic baseline panel before every GLP-1 prescription. HbA1c and fasting insulin reveal glucose dysregulation and insulin resistance—this guides dosing and helps predict gastrointestinal tolerance. A comprehensive metabolic panel (CMP) checks kidney function because these medications are renally cleared; we avoid them in patients with eGFR <30 mL/min/1.73m². Lipase rules out subclinical pancreatitis, which would be a contraindication.
Thyroid function (TSH, free T4) matters because hypothyroidism mimics GLP-1 side effects—fatigue, constipation, cold intolerance—and untreated thyroid disease blunts weight loss response. A lipid panel (total cholesterol, LDL, HDL, triglycerides) establishes cardiovascular risk and provides a marker we re-check at 12 weeks; GLP-1 medications reduce triglycerides 15-20% independent of weight loss.
We also measure body composition via DEXA or bioimpedance analysis. Baseline lean mass percentage predicts who will lose disproportionate muscle during treatment. A 2023 JAMA study found that 25-40% of weight lost on GLP-1 medications is lean tissue—double the percentage seen with diet and exercise alone. Patients starting with low muscle mass need higher protein intake (1.6-2.0 g/kg ideal body weight daily) and structured resistance training from day one.
How do we protect muscle mass during GLP-1 treatment?
Muscle preservation requires deliberate intervention, not passive monitoring. We recommend 1.6-2.0 grams of protein per kilogram of ideal body weight daily, distributed across at least three meals. This typically means 100-150 grams daily for most patients, significantly higher than the spontaneous intake on these appetite-suppressing medications. Whey or plant-based protein supplements become practical necessities when solid food intake drops.
Resistance training at least three times weekly is non-negotiable. The stimulus to preserve muscle must match the caloric deficit. We refer patients to trainers familiar with sarcopenia prevention protocols—compound movements, progressive overload, eccentric emphasis. A 2024 Obesity journal study showed that structured resistance training during semaglutide treatment preserved 90% of lean mass versus 60% with medication alone.
We recheck body composition every 12 weeks. If lean mass drops more than 5% while fat mass drops less than 10%, we adjust the protocol—increase protein, add leucine supplementation (3-5 g per meal), intensify training frequency, or slow the medication titration. Some patients require a brief medication pause to rebuild muscle before continuing. The goal is fat loss, not weight loss at any cost.
What happens when patients stop GLP-1 medications?
Weight regain after discontinuation is the norm, not the exception. The STEP 1 extension study showed that patients who stopped semaglutide after 68 weeks regained two-thirds of lost weight within one year. Ghrelin levels rebound, leptin sensitivity remains impaired, and metabolic rate stays suppressed—the biological systems that drove obesity reassert themselves.
This is not a character flaw; it reflects the chronic nature of obesity as a disease. We discuss this reality before the first injection. Some patients plan for indefinite treatment. Others use a 6-12 month course to achieve initial weight loss, then transition to maintenance strategies—continued high protein intake, resistance training, possibly other medications like metformin or naltrexone-bupropion, and meticulous metabolic monitoring.
The regain risk is highest in patients who lost weight rapidly without building sustainable habits. We slow titration intentionally, allowing 6-9 months to reach therapeutic doses, so patients learn portion control and food choices while appetite is pharmacologically modulated. The medication is training wheels for new eating patterns, not a substitute for them.
What does GLP-1 treatment actually cost?
List prices run $1,000-$1,400 monthly for brand-name semaglutide (Wegovy) and tirzepatide (Zepbound). Insurance coverage is inconsistent—Medicare Part D explicitly excludes weight-loss medications, while commercial plans vary widely. Some cover with prior authorization proving BMI criteria and failed lifestyle intervention; others exclude weight management entirely.
Manufacturer savings programs (Novo Nordisk and Eli Lilly both offer them) can reduce out-of-pocket costs to $25-$500 monthly for commercially insured patients, but eligibility rules are complex and change frequently. Compounded semaglutide from 503A and 503B pharmacies costs $200-$400 monthly and became more accessible during the FDA shortage period, though long-term availability remains uncertain as brand supply normalizes.
We help patients navigate these systems, but cost remains a significant barrier. The clinical reality is that many patients who would benefit cannot afford treatment, and those who start may not sustain it long enough to reach maintenance. This is a structural problem in our healthcare system—a 2023 analysis in JAMA Health Forum estimated that universal coverage would cost $13.6 billion annually but prevent $200 billion in obesity-related disease over 10 years.
What should you ask your physician before starting a GLP-1 medication?
Ask whether you meet evidence-based criteria, not just BMI thresholds. Request the metabolic workup—HbA1c, fasting insulin, lipids, thyroid, kidney function—and ask what your results mean for your cardiovascular and diabetes risk. Ask about baseline body composition measurement and the plan to preserve muscle mass during treatment.
Ask about the titration schedule and what side effects to expect. Nausea, constipation, and fatigue are common in the first 4-8 weeks but usually improve with slower dose escalation. Ask what happens if you need to stop the medication—is there a transition plan, or will you be left to manage regain alone?
Ask about the monitoring schedule: when will labs be rechecked, how often will body composition be measured, and what triggers a dose adjustment or medication pause? Ask about cost and insurance coverage before the first prescription, and whether the practice helps with prior authorizations and appeals. Finally, ask about the physician's experience—how many patients have they started on these medications, what percentage reach goal weight, and how is muscle loss being addressed in their patient population?
These are complex medications for a complex disease. The right answers should be specific, evidence-based, and honest about both the potential and the limitations.
